Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 6,450 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News


All Sessions will remain available on the Attendee Hub until October 1, 2023. Sessions are accessed through the Home page.

SOHO Highlights On-Demand Content

SOHO members and Highlights meeting attendees now have access to the presentations on-demand, as well as speakers' slides. These items will be available through January 27, 2023.

FDA Approves Brentuximab Vedotin for Pediatric High-Risk Hodgkin Lymphoma

The FDA has approved a new indication for brentuximab vedotin for pediatric patients with previously untreated high-risk Hodgkin lymphoma.

UK Regulator Grants ‘Innovation Passport’ Status to ALETA-001 for NHL, ALL

UK regulators granted an Innovation Passport to ALETA-001 for the treatment of patients with NHL and ALL who failed to respond or relapsed after CD19 CAR T-cell therapy.

BLA for Subcutaneous Epcoritamab in LBCL Granted FDA Priority Review

A BLA was granted priority review by the FDA for subcutaneous epcoritamab in the treatment of patients with relapsed/refractory LBCL after two or more lines of systemic therapy.

Off-the-Shelf CAR-T Active in B-Cell ALL

Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in a phase I study of UCART19 in heavily pretreated patients with relapsed or refractory B-cell acute lymphoblastic leukemia

GPRC5D-Targeted CAR-T Leads to 71% Response Rate in Multiple Myeloma

A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma, with comparable results in those who previously received a BCMA-directed therapy.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top